Drug Profile

STE 401

Alternative Names: STE-401

Latest Information Update: 28 Sep 2020

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Stemergie Biotechnology
Class Antineoplastics; Small molecules
Mechanism of Action Electron transport complex I inhibitors; Electron transport complex III inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes - Glioma

28 Sep 2020 No recent reports of development identified for preclinical development in Glioma in Switzerland
10 Aug 2016 STE 401 is available for licensing as of 10 Aug 2016. http://www.stemergie.com/
10 Aug 2016 Preclinical trials in Glioma in Switzerland (unspecified route)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com